BVF Inc. IL Raises Stake in Compass Therapeutics, Inc. $CMPX

BVF Inc. IL lifted its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 63.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 7,764,842 shares of the company’s stock after purchasing an additional 3,014,842 shares during the quarter. Compass Therapeutics comprises approximately 1.4% of BVF Inc. IL’s holdings, making the stock its 25th largest holding. BVF Inc. IL’s holdings in Compass Therapeutics were worth $41,697,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares during the period. Creative Planning purchased a new stake in shares of Compass Therapeutics during the 2nd quarter worth about $30,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth about $32,000. Strs Ohio purchased a new stake in shares of Compass Therapeutics during the 1st quarter worth about $34,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Compass Therapeutics during the 3rd quarter worth about $37,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Up 4.1%

Shares of CMPX opened at $2.05 on Thursday. The business’s 50 day moving average is $2.96 and its two-hundred day moving average is $4.69. Compass Therapeutics, Inc. has a 52-week low of $1.61 and a 52-week high of $6.88. The firm has a market cap of $369.18 million, a price-to-earnings ratio of -5.00 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, equities analysts expect that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. D. Boral Capital reiterated a “buy” rating and set a $30.00 target price on shares of Compass Therapeutics in a report on Monday, April 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a report on Thursday, March 12th. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Raymond James Financial cut Compass Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, April 28th. Finally, Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $12.91.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.